Abstract
Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Current Neuropharmacology
Title:Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Volume: 10 Issue: 3
Author(s): Akiyoshi Saitoh and Mitsuhiko Yamada
Affiliation:
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Abstract: Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Export Options
About this article
Cite this article as:
Saitoh Akiyoshi and Yamada Mitsuhiko, Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217314
DOI https://dx.doi.org/10.2174/157015912803217314 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Child Welfare in Japan: Children’s Care Homes and Mental Health
Adolescent Psychiatry Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Current Pharmaceutical Design Analysis of Soybean Root Proteins Affected by Gibberellic Acid Treatment Under Flooding Stress
Protein & Peptide Letters Editorial (Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine)
Current Pharmacogenomics and Personalized Medicine Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells
Current Drug Targets - Inflammation & Allergy Pharmacology of Adenosine A2A Receptors and Therapeutic Applications
Current Topics in Medicinal Chemistry Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Psychomotor Seizure Screening and in vitro Neuroprotection Assay of Hydrazones Derived from 2-Acetyl Thiophene
Central Nervous System Agents in Medicinal Chemistry Molecular Modelling and QSAR of Reversible Acetylcholines-terase Inhibitors
Current Medicinal Chemistry Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review
Current Neuropharmacology Management of Adult Active Tuberculosis Disease in Era of HIV Pandemic, Current Practices and Future Perspectives
Infectious Disorders - Drug Targets Meet Our Editorial Board Member
Current Psychiatry Reviews The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions
Current Molecular Pharmacology Iridoid Compound 10-O-trans-p-Coumaroylcatalpol Extends Longevity and Reduces Alpha Synuclein Aggregation in Caenorhabditis elegans
CNS & Neurological Disorders - Drug Targets Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry